Facilitating Collaborative Cancer Discovery

Changing the future of cancer, with patients, for patients.

AVATAR offers full access to clinical and complete molecular data for custom patient cohorts. It is the first cancer dataset that connects cancer patients and research, providing valuable multimodal, longitudinal data to inform therapy development, with confidentiality at the core of its design.

Patient Centric




Access Oncology Discovery Data & Custom Cohorts

Aster Insights has cultivated an exclusive clinical network through a one-of-a-kind collaboration between leading bio-pharmaceutical companies and prominent cancer centers across the United States.

With 350,000+ lifetime consented patients in the HIPAA-Compliant Total Cancer CareTM (TCC) Protocol, AVATAR is uniquely designed to help solve target identification, biomarker discovery, and indication strategy.

We do this by providing longitudinal clinical data and highly-curated molecular information — Whole Exome Sequencing (WES), Whole Transcriptome Sequencing (WTS) and Germline sequencing datasets—all while shielding the patient’s identity behind an AVATAR.

The Benefits: Build R&D Connections with AVATAR

By licensing AVATAR, you can explore rich real-world oncology data with:

  • Real-time access
  • Continuous accumulation and expansion of patient data
  • Unparalleled depth and breadth
  • Standardized collection and annotation of complete molecular data
  • Aster’s proprietary analytical toolbox

With AVATAR, you gain unmatched connectivity to real-world oncology data from tens of thousands of consenting cancer patients over their lifetime.

Our pre-defined and precision cohorts, which accurately reflect the nuanced and personal nature of cancer, are driving drug discovery like never before.

AVATAR data is fit for purpose for Oncology Drug Discovery. Researchers can leverage rich clinical genomic data to address specific use cases:

  1. Novel target identification & validation
  2. Biomarker identification & validation
  3. Response identification & validation
  4. Endpoint Analysis
  5. Indication expansion

Patient Centric

AVATAR identifies novel biomarkers associated with treatment responses, informing clinicians of appropriate clinical trial options for their patients.


AVATAR is changing the way scientists design clinical trials, enroll patients, and benchmark their research.


AVATAR is ever-expanding, with an average of ~25,000-30,000 new patients added every year, and the ability to capture data on drugs new-to-market.


AVATAR richness stems from the direct link between patient, researcher and drug developer, allowing the growth of longitudinal data which expedites cancer drug discovery.

What Makes AVATAR So Unique?

18 participating institutions

We serve at the intersection between our Oncology Research Information Exchange Network® (ORIEN) partners and pharma.

350,000+ lifetime-consented patients

Cancer patients are working with science to accelerate the development of more personalized cancer therapies.

30+ Cancer Types | 20,000+ genes

AVATAR houses data covering 20,000+ genes and 30+ types of cancer to allow for custom cohort creation.

325+ Clinical data points per patient

With 22,000+ patients in our cancer database today, AVATAR has comprehensive oncology discovery data paired with 600+ elements of clinical information.

The Aster Insights Mindset

Tackling cancer is personal, on a human level and a molecular level, and our goal is to help people survive and thrive.

But we can’t do it alone. It requires a community of partners working together—patients, cancer research centers, and drug developers—to take on this life altering, highly complex disease. Partners who are in it for as long as it takes, from lifetime-consented patients to long-term disease research studies and drug development programs.

Watch Aster Insights Intro Video


“Aster Insights’ strong foundation of relationships with cancer centers, the life sciences, and pharma is driving the kinds of oncology research that you couldn't do otherwise in industry or academia.”

Dan Elgort, PhD

Chief Data and Analytics Officer

Featured Publication

Related Products & Services

Get answers to targeted oncology research questions by tapping into industry experts at Aster Insights and letting us SEARCH the AVATAR database for you.